Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up
31 Marzo 2023 - 7:00AM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced continued
expansion of the BioXp® Select Kit product line, releasing two
novel kits to enable DNA amplification and scale-up.
The BioXp® Select DNA Cloning and Amplification Kit and the
BioXp® Select Plasmid Amplification Kit enable on-demand and
automated synthesis and amplification of transfection-scale DNA
beginning from the customers own DNA fragments or plasmid DNA,
overnight and at the push of a button. This is expected to enable
researchers to optimize their discovery workflows by reducing the
time and steps for cloning and scale-up of DNA required for their
testing and analysis.
“Common to many workflows is the need to scale DNA constructs to
transfection-scale quantities. The BioXp® System enables one to
automate cell-free DNA amplification and scale-up, reducing time
and eliminating manual bacterial steps. We believe this can
accelerate discovery, particularly in the areas of screening large
number of lead candidates in antibody discovery, cellular
immunotherapy, and protein engineering,” said Daniel Gibson, Ph.D.,
CTO and Co-founder of Telesis Bio.
“These releases represent our commitment to open our platform
and provide scientists the flexibility to adapt the BioXp® System
to their process and begin with their own materials. We believe
that enabling scientists to begin the cloning, amplification, and
mRNA synthesis process from their own linear DNA or plasmid DNA
will empower them to advance their research and accelerate their
discoveries. Throughout 2023, we plan to release additional BioXp®
kits that enable cloning and DNA amplification, as well as to
automate NGS Library Preparation and CRISPR gRNA synthesis,” said
Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio.
For more information on BioXp® Select Amplification Kits or to
place an order,
please visit telesisbio.com/products/bioxp-kits/dna-amplification/
About Telesis BioTelesis Bio is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® systems consolidate, automate,
and optimize the entire synthesis, cloning and amplification
workflow. As a result, they deliver virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp
are trademarks of Telesis Bio Inc.
Forward-Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
include statements and guidance regarding Telesis Bio’s future
financial performance as well as statements regarding the future
release and success of new and existing products and services. Such
statements are based on current assumptions that involve risks and
uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond our control, include risks described in the section entitled
Risk Factors and elsewhere in our Annual Report on Form 10-K, which
was filed with the Securities and Exchange Commission on March 22,
2023. These forward-looking statements speak only as of the date
hereof and should not be unduly relied upon. Telesis Bio disclaims
any obligation to update these forward-looking statements.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Telesis Bio (NASDAQ:TBIO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024